These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221 [TBL] [Abstract][Full Text] [Related]
4. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311 [TBL] [Abstract][Full Text] [Related]
5. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Spencer K; Nicolaides KH BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267 [TBL] [Abstract][Full Text] [Related]
10. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586 [TBL] [Abstract][Full Text] [Related]
11. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764 [TBL] [Abstract][Full Text] [Related]
12. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N; J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837 [TBL] [Abstract][Full Text] [Related]
13. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635 [TBL] [Abstract][Full Text] [Related]
14. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy. Spencer K Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639 [TBL] [Abstract][Full Text] [Related]
15. First trimester predictors of adverse pregnancy outcomes. Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038 [TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443 [TBL] [Abstract][Full Text] [Related]
17. Practical strategies in contingent sequential screening for Down syndrome. Benn P; Wright D; Cuckle H Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988 [TBL] [Abstract][Full Text] [Related]
18. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland. Peuhkurinen S; Laitinen P; Honkasalo T; Ryynanen M; Marttala J Acta Obstet Gynecol Scand; 2013 Jul; 92(7):769-74. PubMed ID: 23369035 [TBL] [Abstract][Full Text] [Related]
19. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220 [TBL] [Abstract][Full Text] [Related]
20. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Wald NJ; Rish S; Hackshaw AK Prenat Diagn; 2003 Jul; 23(7):588-92. PubMed ID: 12868090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]